OHSU

Clinical Trials

The Harold Schnitzer Diabetes Health Center Research Department is committed to promoting and conducting cutting-edge clinical research. Our goal is to enhance the quality of life of those living with or affected by diabetes.

Our efforts to find a cure for diabetes, and to improve life for people with this condition, are made possible by volunteers who participate in research studies. When you volunteer, you help us answer important questions about diabetes.

If you would like to be considered to participate in any of our research studies please call 503 494-4704, or complete our Online Application Form, or email at DMResearchCenter@ohsu.edu for more information.

 

GRADE Study

Study started on: 5/17/13

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

View the Study Brochure

The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, in collaboration with 37 medical clinics, including Oregon Health & Science University, is conducting the GRADE Study (The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study). GRADE is a clinical trial designed for people living with diabetes.  The goal of the study is to find the best combination drug treatment for diabetes.

You may qualify for this study, if you:

  • Have had type 2 diabetes for less than 10 years
  • Are taking metformin as your only diabetes medication 

If you join GRADE, you will:

  • Come to Oregon Health & Science University for four diabetes medical visits each year for up to 7  years
  • Take metformin plus one of 4 other diabetes medications chosen by chance
  • Receive diabetes treatment, FDA approved medicines and supplies at no cost to you
  • Receive physical exams and lab tests at no cost to you
  • Receive $100 at the end of each year as well as $10 per visit 
The GRADE study is being conducted at Oregon Health & Science University.  For more information, and to see if you might be eligible to join, please contact the Harold Schnitzer Diabetes Health Center Research Department GRADE Study Team at (503) 494-4650, by e-mail at GRADE@ohsu.edu, or visit

https://grade.bsc.gwu.edu.      

eIRB #9157

 

Investigational Intranasal Glucagon Study

The OHSU Harold Schnitzer Diabetes Health Center Research Department is conducting a study comparing the safety and effectiveness of intranasal glucagon (a hormone that raises blood sugar) to injected glucagon for treating hypoglycemia. 

You may qualify if you: 

  • Are between 18 and 65 years of age
  • Have type 1 or type 2 diabetes and have used insulin for the last 2 years
  • Are in good general health
Participation in the study will last approximately 1 month and will include a screening visit and two 6 hour visits. All study related care will be provided at no cost. Qualified participants will continue their usual diabetes management regimen at their own expense. Compensation of up to $500 will be provided.

Principal Investigator: Andrew Ahmann, MD

eIRB #9915

 

Type 1 Diabetes Research Opportunity

Study started on: 11/6/13

Currently recruiting patients for this study? No

Principal Investigator is Andrew Ahmann, MD

The OHSU Harold Schnitzer Diabetes Health Center Research Department is conducting a 63-week research study to compare the effectiveness, safety and tolerability of a new, faster acting insulin analogue called FIAsp with the already marketed insulin aspart (Novolog), when used with the long acting insulin detemir. This study is also comparing the control of blood sugars with two different ways of taking a meal time insulin; either before, or after a meal.You may qualify if you:

All study-related care is provided at no cost to qualified participants including physical examinations, a glucose meter and supplies, study drugs and supplies, and laboratory tests. Compensation of up to $1790 will be provided.

  • Are 18 to 80 years of age
  • Have been diagnosed with type 1 diabetes greater than 1 year
  • Currently treated with a basal insulin analogue (any regimen of insulin detemir or insulin glargine) for greater than 4 months
  • Have an HbA1c between 7.0 – 9.5%
  • Not currently using real time CGM system/or willing to NOT use a real time CGM system during the trial


FLAT Sugar Study

Study started on:

Currently recruiting patients for this study? No

Principal Investigator is Andrew Ahmann, MD

Early studies suggest that when people take long-acting insulin and metformin, they have fewer blood sugar extremes when they also take a new type of medicine called glucagon-like polypeptide-1 (GLP-1) agonist named exenatide, instead of meal-time insulin. Participants are asked to take part in an eight month study to find out if middle-aged and older people with Type 2 diabetes who have added risk factors for heart disease have fewer blood sugar extremes when they take exenatide, instead of meal-time insulin, in addition to long-acting insulin and metformin.

You may qualify if you:

Are 40 to 75 years of age with a history of cardiovascular disease, or 55-75 with risk factors for cardiovascular disease

  • Have been diagnosed with type 2 diabetes for at least 12 months
  • Currently take insulin (if on a pump, must be willing to use injections during the study)
  • Are able to tolerate metformin
  • Have a BMI less than 40 kg/m2
  • Have an HbA1c between 7.5-8.5%

 

All study-related care is provided at no cost to qualified participants including physical examinations, a glucose meter and supplies, study drugs, and laboratory tests. Compensation of up to $320 will be provided.

Contact the OHSU Harold Schnitzer Diabetes Health Center Research Department at (503) 494-4704 or by email at DMResearchCenter@ohsu.edu for more information.

eIRB #8463


T1D Exchange Study

Study started on: 8/23/10

Currently recruiting patients for this study? No

Principal Investigator is Andrew Ahmann, MD

Currently, large gaps exist in our knowledge and understanding of the best way to manage type 1 diabetes in children and adults. The overall objective of this study is to improve the care of people with type 1 diabetes through sharing data in a common data repository. This study aims to collect core clinical and laboratory data on persons with type 1 diabetes in order to address important clinical issues, develop new research protocols, and locate participants for future clinical studies.


TrialNet Study

TrialNet Natural History Study of the Development of Type 1 Diabetes and Oral Insulin Study

Study started on: 2/13/2009

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

The purpose of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals. At risk individuals are those that have a blood relative with type 1 diabetes. Close relatives of people with type 1 diabetes are being studied in three steps (phases): Screening, Baseline Risk Assessment, and Follow-Up Risk Assessments.

ITN018A Study


LAR 105 Study

A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.

Study started on: 6/2/2006

Currently recruiting patients for this study? No

Principal Investigator is Andrew Ahmann, MD

The purpose of this study is to look at the safety, tolerability, and effectiveness of an investigational (experimental) injectable drug (exenatide LAR) in people with type 2 diabetes.